News

Three approaches to examination give a comprehensive overview

The approval also grants Outlook Therapeutics an initial 10 years of market exclusivity in the EU for bevacizumab gamma (LYTENAVA)

The light-based therapy functions using a virtual reality headset

Challenging choices force ophthalmologists to weigh long-term outcomes

Inhibiting ferroptosis could be crucial to reducing inflammation

Analysis of the OAKS and DERBY trials showed reduced growth rates of SD-OCT biomarkers for geographic atrophy

Professor Lois accepted the award at the Royal College of Ophthalmologists Annual Congress

The agency issued approval for Yesafili, from Biocon Biologics, and Opuviz, from Samsung Bioepis and Biogen

For decoding biomarkers, a multistage system is just the beginning

Need for accuracy results in optimisation of training for novice surgeons

The implantable lenses can offer an advantage over laser surgery

Promising innovations are not one-size-fits-all

The submission for bevacizumab gamma (ONS-5010/LYTENAVA) follows a positive opinion from the CHMP in March

At the 2024 ARVO meeting, Andrew D. Pucker, OD, PhD, presented a paper on measuring meibomian gland morphology

Allen Ho, MD, presented on the 12-month results of an mutation agnostic optogenetic programme at the ARVO 2024 meeting

Three leaders in glaucoma research, retina care and refractive surgery share their expertise

Astigmatic values differed between K and TK readings

At this year's ARVO meeting, the Eye Care Network got a glimpse at the future of paediatric myopia control research

Considering ages and stages of myopia progression in a therapeutic timeline

Incoming ARVO president SriniVas R. Sadda, MD, discussed major challenges in vision science research and how annual meetings inspire innovation in ophthalmology

Elias Kahan speaks about his ARVO poster, "Contact specular microscopy reliably images the same location of the corneal epithelium"

The mutant huntingtin protein in tear fluid may have the potential to serve as an early marker of changes in Huntington disease

At this year's ARVO meeting, Neda Gioia, OD, discussed the increasing patient burden of dry eye disease

Eric Donnenfeld, MD, discusses the clinical evaluation of Blink Triple Care artificial tears ahead of the 2024 ARVO meeting

John Sheppard, MD, MSc, FACs, discusses the unique biochemical traits of perfluorohexyloctane for eye dry disease and meibomian gland dysfunction